Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Nivolumab potentially superior to standard chemo in advanced melanoma

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma

Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma

Combining cobimetinib and vemurafenib improves progression-free survival in advanced melanoma

Benefits of investing in skin cancer prevention

Preventing skin cancer worldwide and the impact of different regulatory and economic priorities

The Euro Melanoma campaign and the importance of communication, education, and understanding of skin cancer

Overview of skin cancer treatments, past, present and future

Skin cancer across the world and ways of preventing risk

Biomarker found to aid in screening of squamous cell carcinoma